MedPath

Protocol for a study on male patients suffering from peripheral arterial disease with severe chronic limb ischemia during treatment with iloprost: assessment of oxidative stress and organic erectile dysfunction - ND

Conditions
peripheral arterial disease and organic erectile dysfunction.
MedDRA version: 9.1Level: SOCClassification code 10047065Term: Vascular disorders
Registration Number
EUCTR2008-006304-38-IT
Lead Sponsor
POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
Male
Target Recruitment
Not specified
Inclusion Criteria

Sex: male
Married
Peripheral arterial disease not eligible for revascularization
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Eligibility for revascularization
Inflammatory diseases
Cancer
Obesity
Intolerance to the drug (iloprost)
Haemorrhagic risk: peptic ulcer, trauma, cerebral haemorrhage
Acute or chronic cardiac failure (NYHA II-IV)
Severe coronary artery disease or unstable angina
Myocardial infarction in the previous six months
Severe arrhythmias
Suspicion of pulmonary congestion
Current use of antioxidant drugs
Smoking
Current use of beta-blockers, clonidine, alphamethyldopa and major analgesic drugs

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Main Objective: to evaluate the variation of oxidative stress (hydroperoxide blood level) and of erectile dysfunction in patients affected by peripheral arterial disease, not eligible for revascularization, during treatment with iloprost.;Secondary Objective: nd;Primary end point(s): nd
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath